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The recent prospect of pharmaceutical interventions for cognitive impairment of Down
syndrome (DS) has boosted a number of clinical trials in this population. However,
running the trials has raised some methodological challenges and questioned the
prevailing methodology used to evaluate cognitive functioning of DS individuals. This
is usually achieved by comparing DS individuals to matched healthy controls of the
same mental age. We propose a new tool, the TESDAD Battery that uses comparison
with age-matched typically developed adults. This is an advantageous method for
probing the clinical efficacy of DS therapies, allowing the interpretation and prediction
of functional outcomes in clinical trials. In our DS population the TESDAD battery
permitted a quantitative assessment of cognitive defects, which indicated language
dysfunction and deficits in executive function, as the most important contributors to
other cognitive and adaptive behavior outcomes as predictors of functional change in
DS. Concretely, auditory comprehension and functional academics showed the highest
potential as end-point measures of therapeutic intervention for clinical trials: the former
as a cognitive key target for therapeutic intervention, and the latter as a primary functional
outcome measure of clinical efficacy. Our results also emphasize the need to explore the
modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably,
women performed significantly better than men of the same age and IQ in most cognitive
tests, with themost consistent differences occurring inmemory and executive functioning
and negative trends rarely emerged on quality of life linked to the effect of age after
adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool
for probing the clinical efficacy of experimental therapies in interventional studies in the
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DS population suggesting that age-matched controls are advantageous for determining
normalization of DS.
Keywords: Down syndrome, TESDAD neurocognitive battery, intellectual disabilities, cognition, clinical trials as
topic
Introduction
Down Syndrome (DS) is the most common genetic cause of
mental retardation (Megarbane et al., 2009), with an incidence
of approximately 9.65 for every 10,000 live births in Europe
(Khoshnood et al., 2011). Although most of its phenotypic
features are variable, both in prevalence and expression, the DS
neurocognitive profile is characterized by psychomotor delay and
a general, and pronounced, deficit in learning/memory, executive
functions, and language abilities that shape the intellectual
disability of the syndrome (Pennington et al., 2003; Rowe et al.,
2006; Vicari, 2006; Iacono et al., 2010). The recent flourishing
of therapy-oriented research in DS has led to an increasing
number of clinical trials that require validated test batteries to test
treatment efficacy and safety. Research in the field of cognitive
enhancers for mental health is moving toward considering key
brain networks and specific areas underlying major cognitive
deficits as the main targets for therapeutic intervention,
instead of focusing on broad-based neurotransmitter systems.
In parallel, there is the pressing need to update the diagnostic
classification schemes and the neuropsychological assessment
methods according to this new neuroscience-based approach
(Insel et al., 2010, 2013). Furthermore, few of the plethora of
methods for cognitive assessment report clinically significant
psychometric data for DS subjects, and neither do they
suitably accommodate the heterogeneous range of impairments
experienced by this population.
The prevailing methodology used to characterize cognitive
functioning compares DS subjects, or those with other learning
disabilities of genetic origin (e.g., Williams-Beuren and Fragile-
X Syndromes) or unknown etiology, to healthy controls of the
same “mental age.” The comparison is assumed to provide an
index of global level of mental maturation (Edgin et al., 2010b;
Finestack and Abbeduto, 2010; Costanzo et al., 2013a). These
approaches are based on the notion that the mental maturation
rate in subjects with intellectual disability differs substantially
from typically developed subjects of equal chronological age,
but should not differ significantly, or only in certain capacities,
when matched for their “mental age” (Costanzo et al., 2013b).
Whilst this perspective has been valuable for characterizing the
DS cognitive phenotype, it is not useful for determining the gap
in cognitive performance betweenDS subjects and healthy adults,
which is the cognitive target we aim for in clinical trials. The few
studies that have used an age-matched healthy population with
standard norms have focused on the study of specific cognitive
domains (e.g., language and memory processing), but have not
carried out a comprehensive description of the DS profile (Næss
et al., 2011).
Cognitive-enhancing therapies aim to bring cognitive and
functional competence in DS closer to the standards expected
for their chronological age. We propose, therefore, to use an age-
matched healthy control population for the systematic evaluation
of the reduction, stabilization, or slowing of the cognitive
and functional performance of DS with respect to therapeutic
interventions. From a clinical point of view, standard norms
from healthy subjects provide a feasible and valuable reference
for quantifying the magnitude of cognitive improvement needed
for functional changes. For example, modest cognitive gains
related to experimental treatments in DS subjects, which would
be considered of subclinical magnitude in typically developed
adults, could imply a mild but clinically meaningful and
significant impact on everyday life functioning in the DS
population, which is harder to determine using mental age or
mentally disabled-matched subjects as a comparison.
We have developed the TESDAD battery for clinical trials
to characterize the cognitive functioning of young adults with
DS, within mild to moderate–severe intellectual disability, using
standard norms from age-matched typically-developed adults as
a reference for this characterization. The TESDAD battery was
used to explore the relative contribution of intellectual quotient
(IQ), gender, and age to neurocognitive variability among
DS participants, and to identify specific relationships between
cognitive performance and different aspects of functional
outcome that could potentially serve for expecting functional
change in interventional studies.
Methods
Participants
Eighty-six young adults of both genders with DS, aged 16–34
years, with any of the three DS genetic variations (trisomy
21, mosaic, or translocation) were enrolled in the study,
mainly through the Fundació Catalana de Síndrome de Down
(Barcelona) a local foundation specialized in providing health
care services and educational programs to participants with DS
and their families.
The data reported in the present work correspond to the
baseline cognitive performance of a cohort of DS participants
that participated in a clinical trial NCT01699711, that has been
registered in https://clinicaltrials.gov/ct2/show/NCT01699711.
All participants were drug free during the baseline assessment.
Upon arrival at the research center (Hospital del Mar
Medical Research Institute-IMIM), participants, parents and
legal guardians (in case of legal incapacitation) were informed
of the ensuing protocol and they gave their written informed
consent before participating. Subjects with neurological disease
other than DS, relevant medical disease, unstable co-morbid
mental disorder or currently taking any treatment that could
interfere with cognitive function were excluded from the study.
Other exclusion criteria applied to all the participants were: (i)
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having suffered from any major illness or undergoing major
surgery in the last 3 months before the study; (ii) new or irregular
medication in the month preceding the study; (iii) current
ingestion of vitamin or catechins supplements or Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) in the 2 weeks preceding the
study; (iv) history of gastrointestinal, hepatic, renal, or any other
problems that may alter absorption, distribution, metabolism, or
excretion of the drug. Genetic variations were documented by
chromosomal analysis.
Test Procedure and Customized
Neuropsychological Test Battery
The study was conducted in accordance with the ethical
standards laid down in the Declaration of Helsinki and
approved by the local ethics committee (CEIC-Parc de Salut
Mar). At study onset the participants underwent medical
examinations and a brief cognitive assessment to estimate their
intellectual disability level based on criteria from the Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition-Text
Revision (American Psychiatric Association, 1994). A trained
evaluator then individually assessed the participants in a 90-
min session aimed at exploring a wide range of cognitive and
functional domains. The cognitive tests were presented in a fixed
order to allow adequate intervals for delay trials on measures
of episodic memory (see Supplementary Table B.1.). All tasks
were carried out in a quiet, comfortable room.While participants
completed the neuropsychological testing, parents, caregivers or
legal guardians answered questionnaires measuring functionality
in the participants’ daily lives using questionnaires for the
following domains: adaptive behavior, quality of life (QoL),
quality of sleep, and neuropsychiatric symptoms. Measures of
adaptive behavior were obtained with the adult version of the
Adaptive Behavior Assessment System-Second Edition (ABAS-
II). Quality of life was assessed with the parents’/guardians’
version of the Kidscreen-27. Quality of sleep was explored with
The Pittsburgh Sleep Quality Index (PSQI), and neuropsychiatric
symptoms were assessed with the Neuropsychiatric Inventory
(NPI). IQ was estimated using The Kaufman Brief Intelligence
Test (K-BIT). A more detailed description of the complete
neuropsychological battery and references can be found in the
Supplemental Materials (A.1 and A.2). None of the participants
required the presence of their parents or legal guardians to
perform cognitive testing.
Neuropsychological Testing
The following cognitive domains were explored: psychomotor
speed, attention, episodic memory, executive functions, and
language. Several tests from the Cambridge Neuropsychological
Test Automated Battery (CANTAB) (Robbins and Sahakian,
1996) were employed in addition to standard paper and
pencil tests. Psychomotor speed was measured with the Motor
Screening Test (MOT, CANTAB). Attention was assessed by
means of simple reaction time and span capacity measures using
the Simple Reaction Time task (SRT, CANTAB), the Spatial
Span forward recall (SSP, CANTAB) and the Digit Span forward
recall from the Wechsler Adult Intelligence Scale-III (WAIS-
III) that evaluated visual and verbal information, respectively.
Measures of visual episodic memory and learning were obtained
using the CANTAB Paired Associates Learning (PAL) and the
Pattern Recognition Memory Test (PRM, CANTAB), and verbal
episodic memory using the Cued Recall Test (CRT). Regarding
executive functioning, fractioned components of verbal fluency,
working memory, planning, mental flexibility, and inhibitory
control were explored. Verbal word fluency was measured by
means of the semantic fluency word generation task (animals in
1min). Working memory for visual and verbal information was
assessed with the Spatial Span backward recall (SSP, CANTAB)
and the Digit Span backward recall (WAIS-III), respectively.
Planning capacity was measured using the Tower of London
from Drexel University (ToLDx) and mental flexibility with
the Weigl Color-Form Sort Test. The Cats and Dogs Test
was used to assess response inhibition. Finally, measures of
expressive and receptive language were obtained by means of
the Boston Naming Test and the Token Test, respectively. Only
adult versions of the selected cognitive tests were employed with
the exception of three specific tests for adults with intellectual
disability due to the complexity of the tasks. These included
the assessment of verbal episodic memory (Cued Recall Test),
executive components of inhibition (Cats and Dogs) and mental
flexibility (Weigl Sorting Test). We also administered the child’s
version of the ToLDx for the planning task to avoid floor
effects. The cognitive tests were presented in a fixed order to
allow adequate intervals for delay trials on measures of episodic
memory. In addition, parallel versions of episodic memory
tests were used to control for learning effects. Regarding the
tests selected from the CANTAB, only clinical versions were
administered.
To perform the comparison of our sample of DS participants
with typically developed participants, test scores from normative
data provided by the test publishers and normative studies for
subjects of the same age range of our study (16–39 years)
were employed. (1) For the analyses of CANTAB tests, we
used norms derived from 51 to 199 control subjects reported
in the CANTAB standard norm database (see Robbins et al.,
1997, 1998, for a description of part of these data1. The
Cambridge Cognition website http://www.cambridgecognition.
com/technology provides a practical demonstration of the tests
used). (2) For the analyses of paper and pencil tests, we used
normative data from 84 to 87 participants (18–34 years old) from
the Spanish Multicenter Normative Studies NEURONORMA
young adults Project; (Peña-Casanova et al., 2012). (3) For the
analyses of ToLDx results, as a child’s version had been used,
normative data from 76 participants (13–15 years) was selected
(Culbertson and Zillmer, 2005), so that it better matched our
sample. Similar analyses could not be carried out for performance
on verbal episodic memory, mental flexibility, and response
1Tables for the Cantab test battery are provided in electronic format alongside
the product as standard. This allows the replicability of the present data reported
in this paper. Due to the fact that norms are copyrighted material, these can’t
be reproduced in the present study. In the specific case of the Cantab tests, the
papers cited report only part of the normative sample included in the current
norms, therefore do not correspond precisely to the figures. The present figures
correspond to the current Cantab norms, as available with the test.
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inhibition, due to the lack of normative data from typically
developed adults for these tests.
This battery was developed, and is currently being used,
in a longitudinal, randomized, double blind, placebo-controlled
Phase II trial conducted by our research team in young adults
with Down syndrome (the TESDAD study; De la Torre et al.,
2014). In the present work, only baseline neurocognitive results
from the TESDAD study are reported.
Statistical Analysis
The first step consisted of a descriptive analysis of the
sociodemographic and clinical parameters of all the participants
at baseline. Descriptive analyses were also carried out for
all neuropsychological variables, providing measures of mean,
standard deviation, and maximum and minimum values in the
case of quantitative variables. In order to detect the presence of
significant ceiling or floor effects in the variables, frequencies
and percent were computed. Variables in which more than 10%
of the sample obtained the maximum or the minimum score,
and/or exhibited a significant absolute skewness index (>2) were
categorized as having ceiling or floor effects.
We compared the DS group test scores of each cognitive
variable to previously published normative data from age-
matched healthy controls. Test scores of our DS participants
could not be compared to normative data for those tests
specifically developed for the assessment of participants with
intellectual disability (CRT, Weigl, Cats and Dogs). In order
to quantify and determine the gap between DS and normative
groups, Cohen’s effect size (“Cohen’s d”), which is the difference
of the means of two independent samples divided by the pooled
standard deviation, together with its 95% confidence interval was
calculated for all cognitive variables (Choen, 1988). Effect size
differences higher than one and a half pooled standard deviations
(|d| > 1.5) in cognitive performance between DS participants
and age-matched normally developed adults were considered
key cognitive processes substantially impaired in DS. In order
to assess the severity of impairment the following categories
were established: severe impairment (effect size differences larger
than three pooled standard deviations: |d| > 3); substantial
impairment (|d|> 1.5); moderate impairment (|d|> 1); and mild
impairment (|d| > 0.5).
To study possible differences in cognitive and functional
performance according to IQ, gender, and age, ANCOVAmodels
were fitted for all neurocognitive measures including these three
variables of interest. For the analyses, the IQ was categorized
into two groups: mild/moderate (IQ ≥ 40) and severe (IQ
<40) within the range of mental disability level. Concerning
the two categorical variables, these models provide an adjusted
estimation of the mean differences between persons with DS
with IQ < 40 and persons with DS with IQ ≥ 40, on one
hand, and female and male persons with DS, on the other
hand. In case of variable age, the models provide an adjusted
estimation of the mean difference associated to 1 year of age
difference in persons with DS. The differences were considered
to be statistically significant if the resulting p-value was less
than 0.05. Finally, to explore the relationships between cognitive
performance and functional outcome, the Pearson correlation
coefficient was calculated to determine associations between
cognitive variables, IQ (K-BIT standardized score) and functional
outcomes of adaptive behavior and quality of life. We only report
moderate and strong correlations (r≥ 0.4). All statistical analyses
were performed with the statistical software package R (The R
Foundation for Statistical Computing), v3.0.2.
Results
Descriptive Demographic and Clinical Data of the
Participants
Socio-demographic data and clinical parameters of the 86 DS
participants are provided in Table 1. 51.2% were male and the
mean age was 23.3 years [standard deviation (SD) = 4.3 years;
range 16–34 years]. The median IQ for the full sample was 41
[K-BIT standardized score: 105 (SD = 17.8; range 80–180; IQ
score (SD) = 8.3; range 40–86)], concentrating a slightly higher
proportion of participants with moderate intellectual disability
(IQ ≥ 40: 58.1%; n = 50) in comparison to those within the
severe mental disability range (IQ < 40: 41.9%; n = 36). In terms
of gender, the median IQ for males was 40 [K-BIT standardized
score: 102 (SD = 19; range 80–180)] and 42 for females [K-BIT
standardized score: 108 (SD = 16; range 80–154)]. The average
TABLE 1 | Sociodemographic characteristics and clinical parameters at
baseline.
(n = 86)
AGE 23.3 (4.3)
GENDER
Female 42 (48.8%)
Male 44 (51.2%)
EDUCATION (YEARS)a 13 (1.9)
HANDEDNESS
Right 67 (79.8%)
Left 17 (20.2%)
INTELLECTUAL DISABILITY LEVEL
Mild/moderate (IQ ≥ 40) 50 (58.1%)
Severe (IQ < 40) 36 (41.9%)
INTELLECTUAL QUOTIENT (IQ)
IQ 41b
K-BIT standardized score 105 (17.8)
Male (standardized; IQ) 102 (19); 40b
Female (standardized; IQ) 108 (16); 42b
DS GENETIC VARIATIONS
Trisomy 21 82 (95.3%)
Mosaic 1 (1.1%)
Translocation 2 (2.3%)
Partial 1 (1.1%)
Results are presented as mean (standard deviation) for continuous variables and absolute
frequency (relative frequency) for categorical variables.
aAverage years of school attendance in specialized or non-specialized educational
centers.
bOnly the median is reported because values below 40 cannot be determined exactly.
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years of schooling (regular school attendance in specialized or
non-specialized educational centers) was 13 (SD = 1.9; range
10–18). In terms of DS genetic variations, the sample showed
the usual proportion for this population: most participants had
full trisomy 21 (simple: 95.3%, n = 82), two participants
translocation (2.3%), one partial trisomy (1.1%), and one mosaic
(1.1%).
From the eighty-six participants that participated in the
study, 75 were able to reliably complete all cognitive procedures
at baseline. Eleven participants could not perform the entire
cognitive assessment protocol due to cognitive or behavioral
alterations that interfered with testing. From those, 7 participants
presented marked language deficit (significant speech and/or
comprehension limitations), and 3 participants presented
behavioral disturbances or mental block. One case showed poor
collaboration during the assessment. Only data from these 11
participants for those tests successfully completed were included
in the analyses.
Ceiling effects were found for a few variables in the following
tests: the Cued Recall test (CRT), the Paired Associates Learning
(PAL), the Cats and Dogs and the Simple Reaction Time (SRT).
These were observed in the CRT for the total immediate recall
(A1–A3 total recall) and the total delayed recall, in the PAL for
the number of stages completed, in the Cats and Dogs for the
correct score, and in the SRT for the percent of correct answers.
Regarding floor effects, only a few were detected in the verbal and
visual span backwards (Digit and SSP Visual Span) and in the
total score of the Weigl Sort Test.
Cognitive Performance in DS Participants
Compared to Standard Norms
Descriptive analyses, Cohen effect sizes (d), and confidence
intervals (95% CI) of cognitive performance in DS and age-
matched typically developed adults are summarized in Table 2.
Cohen effect sizes on the differences of cognitive performance
between DS young adults and euploid subjects revealed the
following continuum in the magnitude (d) of the deficits in DS:
a severe dysfunction of language capacity, a substantial deficit
on attention span and executive functions, a moderate deficit in
episodic memory and learning abilities, and mild differences in
psychomotor speed (Figure 1).
Impact of Intellectual Quotient (IQ), Gender, and
Age on Cognitive Performance and Functional
Outcomes
ANCOVA models were applied to analyze effects of IQ, gender,
and age on the baseline cognitive performance of DS participants,
adjusting for co-variables (Tables 3–5). IQ was related to the
significant (p < 0.05) differences in measures of cognitive
capacity between participants of IQ < 40 and those of IQ ≥
40, with the exception of performance on the SRT, Digit Span
Backwards and the Weigl Sort Test. These assessing reaction
time, verbal working memory and mental flexibility, respectively.
As expected, in all cases higher IQ levels were associated with
greater cognitive attainment irrespective of chronological age
or gender (i.e., comparing subjects of equal age and gender).
In addition, significant effects of IQ level were observed in
adaptive behavior in most functional skill areas assessed with the
ABAS-II such as Communication, Community Use, Functional
Academics, Home Living, Health and Safety, Self-Direction,
Social Skills, and ABAS total score (p < 0.05). Once again, those
participants with higher IQ showed better outcomes in adaptive
behavior and thus better competence in daily living. However, no
significant effect of IQ emerged on the Kidscreen-27 (p > 0.05)
which assessed different aspects of quality of life.
Concerning gender, significant differences between men and
women were mainly observed in cognitive performance and
less in functional outcomes. Women performed significantly
better than men of the same age and IQ in most cognitive tests
(Tables 3–5), with the most consistent differences occurring in
episodic memory and executive functioning (Figure 2). Women
also responded better in episodic memory tests, in particular
visual associative memory (PAL) and free recall of verbal
information (CRT) (p < 0.05), but not in visual memory
recognition (PRM; p > 0.05). Concerning executive functions,
women showed significantly better performance (p < 0.05) in
cognitive flexibility and planning. Furthermore, they exhibited
higher scores in receptive language and attention measures of
span capacity, and better accuracy in the simple reaction time
task (p < 0.05). Gender-related differences were also observed
in the functional domain, with women having a significantly
better performance than men in adaptive behavior, specifically
in Functional Academic (emergent literacy and numeracy basics
for current life use) (p < 0.05), but described lower health
perception regarding their physical wellbeing as reported by
parents on the Kidscreen-27 (Kidscreen 27-Physical; p = 0.04).
Overall, these results indicate that gender exerts significant
effects on cognitive and functional capacities in DS participants,
favoring women against men in cognitive functioning and
adaptive skills but not in QoL.
Significant negative trends rarely emerged on quality of
life outcomes linked to the effect of age in DS participants
after adjusting for IQ and gender. Age did not affect adaptive
behaviors, nor most measures of quality of life significantly.
However, age did affect psychological well-being, which affected
total quality of life (p < 0.03). Parents responding to the
Kidscreen 27 Psychological and Total score items indicated
poorer psychological wellbeing and overall health perception as
the children grew older.
Relationship between Cognitive Deficits and
Functional Outcome
The Pearson correlation coefficient was calculated to assess the
relationships between cognition and functionality, in order to
identify meaningful cognitive measures of potential change for
clinical trials. Moderate associations emerged among a wide
spectrum of cognitive measures and IQ with specific adaptive
skills, or the total score in the ABAS-II, while no association was
detected with quality of life measures.
The strongest associations were found between cognitive
performance and functional academic skills (ABAS-II). Positive
associations emerged between Functional Academics and
measures of receptive and expressive language (Token Test:
r = 0.65, [0.51, 0.76]; Boston Naming: r = 0.42, [0.22, 0.58]) and
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TABLE 2 | Cognitive performance in Down syndrome participants compared to standard norms.
Groups Down syndrome Reference standard norms Cohen’s-db 95% CIc
Mean (SD)a Range Age n Mean (SD) Range Age n
(min–max) range (min–max) range
ATTENTION
SRT: simple RT latency (msd) 588.0 (220.0) 302–1430 16–34 85 – – – – – –
SRT: simple RT(%) correct 96.6 (5.7) 68–100 16–34 85 – – – – – –
SSP visual span 3.2 (1.5) 0–6 16–34 86 6.7 (1.3) 3–9 16–39 199 −2.5 −2.8, −2.2
Digit span 2.8 (0.8) 0–4 16–34 86 6.2 (1.0) 4–9 18–34 84 −3.6 −4.1, −3.1
PSYCHOMOTOR SPEED
MOT: mean latency (ms) 1138.0 (391.0) 576–2645 16–34 86 928.0 (254.0) 445–2204 16–39 143 0.7 0.4, 0.9
VISUAL EPISODIC MEMORY
Visual associative memory
PAL: stages completed 6.7 (1.8) 1–8 16–34 85 8.0 (0.04) 7–8 16–39 175 −1.2 −1.5, −0.2
PAL: first trial memory 11.0 (4.8) 0–21 16–34 85 21.6 (3.5) 7–26 16–39 146 −2.6 −3.0, −2.3
PAL: total errors adjusted 70.1 (60.90) 6–213 16–34 85 7. 2 (9.1) 0–82 16–39 168 1.7 1.4, 2.0
Visual recognition
PRM: (%) immediate recall 66.9 (19.3) 25–100 16–34 86 87.8 (12.5) 58.30–100 16–39 51 −1.2 −1.6, −0.8
PRM: (%) delayed recall 61.0 (18.6) 25–100 16–34 85 – – – – – –
EXECUTIVE FUNCTIONS
Verbal fluency
Semantic word fluency 9.4 (4.3) 0–21 16–34 85 23.6 (4.9) 9–34 18–34 87 −3.1 −3.5, −2.6
WORKING MEMORY
SSP visual span backwardse 2.4 (1.6) 0–8 16–34 85 5.0 (0.9) 3–7 18–34 87 −1.9 −2.3, −1.6
Digit span backwards 1.4 (1.2) 0–3 16–34 86 5.2 (1.3) 3–8 18–34 84 −3.0 −3.4, −2. 6
Planningf
ToLDx: total correct Score 1.7 (1.4) 0–5 16–34 82 4.4 (1.7) – 13–15 76 −1.8 −2.1, −1.4
ToLDx: total move score 84.7 (39.2) 0–170 16–34 82 29.0 (13.5) – 13–15 76 1.9 1.5, 2.2
ToLDx: probl-solving time (sg) 763.0 (289.0) 0–1200 16–34 82 214.7 (98.3) – 13–15 76 2.5 2.1, 2.9
LANGUAGE
Comprehension
Token Test: total score 19.6 (6.5) 1–35 16–34 85 35.5 (0.7) 33–36 18–34 87 −3.4 −3.9, −3.0
Naming
Boston Naming Test: total score 24.0 (9.5) 0–53 16–34 82 52.4 (4.3) 39–59 18–34 87 −3. 9 −4.4, −3.4
a Results are presented as mean (standard deviation).
b Cohen’s effect size. Differences larger than three pooled standard deviations: |d| > 3); substantial impairment (|d| > 1.5); moderate impairment (|d| > 1); and mild impairment (|d| >
0.5).
c Confidence Interval.
d Milliseconds.
e Results are compared to standard norms from the Corsi Block provided by the NEURONORMA young adults Project.
f Results are compared to standard norms from adolescent typically developed subjects, ages 13–15 years.
g Seconds.
executive components of verbal fluency (Semantic word fluency:
r = 0.40, [0.20, 0.56]). Positive associations were also found
for working memory for visual and verbal information (SSP
span backwards: r = 0.47, [0.29, 0.62]; Digit span backwards:
r = 0.48, [0.30, 0.63]), planning (ToLDx Total correct score:
r = 0.53, [0.35, 0.67]), attention span for visual and verbal
information (SSP span: r = 0.56, [95%-CI: 0.39, 0.69]; Digit
span: r = 0.46, [0.28, 0.62]), and memory recognition for
immediate and delayed recall of visual information (PRM (%)
immediate recall: r = 0.45, [0.26, 0.60]; PRM (%) delayed
recall: r = 0.48, [0.29, 0.63]). Negative associations were found
between Functional Academics and error rate in the visual
associative learning task (PAL total errors adjusted: r = −0.56,
[−0.69, −0.39]) and planning accuracy deficits (ToLDx Total
move score: r = −0.51, [−0.66,−0.33]). These results indicate
that higher attainment in functional academic skills (emergent
literacy and numeracy basics for current life use) could be
strongly linked to a more efficient overall cognitive functioning
in DS participants. In addition, a positive consistent association
emerged between Functional Academics and IQ (IQ: r = 0.52,
[0.35, 0.66]). These results confirm previous assumptions,
and suggest that specific cognitive measures are potentially
good end-point measures for estimating changes in functional
outcome in clinical trials.
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FIGURE 1 | Radar plot representing the severity of cognitive
impairment in Down syndrome (DS) compared to age-matched
typically developed adults on attention, memory, language and
executive functioning components. Axis values indicate the absolute
value of Cohen’s effect size (d) for the differences between both populations.
For this purpose, the performance of the participants with DS has been
standarized to 1 which is equivalent to an effect size of d = 0. DS adults
show a severe dyfunction of language capacity (|d| > 3), a substantial deficit
on attention span and executive functions (|d| > 1.5) and a moderate deficit
in episodic memory(|d| > 1).
Communication and Community use subscales of the ABAS-
II also correlated consistently with cognitive attainment. Positive
correlations were found between communicative abilities and
visual attention span (SSP span: r = 0.40, [0.20, 0.56]),
receptive and expressive language (Token Test: r = 0.52,
[0.34, 0.66]; Boston Naming Test: r = 0.41, [0.21, 0.58]). In
addition, a negative association was observed between ability
to communicate and the number of errors performed during
visual associative learning (PAL total errors adjusted: r =
−0.46, [−0.61,−0.27]). Community use was mainly related to
cognitive measures of receptive language (Token Test: r = 0.52,
[0.30, 0.63]) and executive components of working memory for
visual and verbal information (SSP span backwards: r = 0.43,
[0.24, 0.59]; Digit span backwards: r = 0.41, [0.21, 0.57]) and
planning (ToLDx Total correct score: r = 0.40, [0.19, 0.56]).
In all cases, a higher performance in specific cognitive tests was
consistently related to a greater ability to communicate in daily
life and higher independent functioning within the community.
Finally, language comprehension emerged as having the most
consistent association with the overall score in adaptive behavior
(ABAS Total Score) (Token Test: r = 0.52, [0.35, 0.66]).
Other cognitive measures were consistently correlated with the
ABAS Total Score such as visual attention span (SSP span:
r = 0.40, [0.20, 0.56]) and executive components of visual
working memory (SSP span backwards: r = 0.41, [0.22, 0.57])
and planning (ToLDx Total correct score: r = 0.41, [0.21,
0.58]; ToLDx Total move score: r = −0.48, [−0.63,−0.29]).
These results indicate that better language comprehension,
attention, and executive functioning are the cognitive capacities
more closely related to higher competence in overall adaptive
skills and, therefore, in everyday life independence for DS
participants.
Discussion
This study proposes a new neurocognitive battery for clinical
trials in DS adults (the TESDAD battery), using chronologically
age-matched fully-developed subjects for comparison as a more
useful approach for the characterization of the DS cognitive
profile. This battery also provides clinically useful measures
closely linked to prefrontal-temporal brain networks and to
functional competence in everyday life following interventional
studies. Finally, our study emphasizes the need to determine the
modulation effects of intellectual quotient, gender, and age on
cognitive treatments.
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TABLE 3 | Impact of intellectual quotient, gender, and age on attention, psychomotor, memory, and language performance in Down syndrome
participants.
Down syndrome Intelligence quotient (<40 vs. ≥ 40) Gender (female vs. male) Age
Estimatea 95% CIb p-values Estimatec 95% CI p-values Estimated 95% CI p-values
ATTENTION
SRT: simple RT latency (mse) 57.2 [−39.1; 153.6] 0.24 −37.7 [−134.2; 58.8] 0.44 8.68 [39.1; 153.6] 0.13
SRT: simple RT(%) correct −1.9 [−4.3; 0.5] 0.12 2.8 [0.3; 5.2] 0.02* −0.25 [−0.5; 0.03] 0.08
SSP visual span −0.8 [−1.4;- 0.2] 0.01* 0.7 [0.1; 1.3] 0.02* −0.03 [−0.0; 0.03] 0.34
Digit span −0.4 [−0.7;- 0.03] 0.03* 0.3 [0.01; 0.7] 0.04* 0.02 [−0.01; 0.06] 0.20
PSYCHOMOTOR SPEED
MOT: mean latency (ms) 176.1 [9.3; 342.9] 0.03* 3.6 [−164.2; 171.4] 0.96 15.7 [−4.2; 35.5] 0.12
EPISODIC MEMORY
Visual associative memory
PAL: stages completed −1.0 [−1.8;-0.3] 0.006** 1.30 [0.6; 2.0] 0.001** 0.02 [−0.06; 0.10] 0.61
PAL: first trial memory −1.8 [−3.7; 0.2] 0.07+ 3.47 [1.5; 5.4] 0.001** 0.002 [−0.2; 0.2] 0.98
PAL: total errors adjusted 35.1 [11.8; 58.4] 0.004** −52.24 [−75.6;-28.9] <0.001*** 0.1 [−2.7; 2.9] 0.94
Visual recognition
PRM: (%) immediate recall −12.1 [−20.2; −4.1] 0.004** 4.25 [−3.8; 12.3] 0.29 −0.6 [−1.6; 0.3] 0.20
PRM: (%) delayed recall −8.0 [−16.0; 0.01] 0.05+ 2.04 [−6.0; 10.1] 0.61 −0.7 [−1.6; 0.3] 0.15
Verbal episodic memory
CRT:A1-A3 free immediate recall −2.5 [−5.0; 0.1] 0.05+ 3.6 [1.0; 6.1] 0.007** 0.1 [−0.2; 0.4] 0.68
CRT:A1-A3 total immediate recall −0.7 [−1.5; 0.2] 0.11 0.8 [−0.01; 1.7] 0.05+ 0.03 [−0.1; 0.1] 0.48
CRT: free delayed recall −0.9 [−2.0; 0.2] 0.11 1.5 [0.4; 2.6] 0.008** 0.1 [−0.1; 0.2] 0.33
CRT: total delayed recall −0.1 [0.4; 0.2] 0.45 0.05 [−0.2; 0.3] 0.68 0.02 [−0.01; 0.05] 0.24
LANGUAGE
Comprehension
Token Test: total score −5.6 [−8.1; −3.0] <0.001*** 3.25 [0.7; 5.8] 0.01* 0.01 [−0.3; 0.3] 0.97
Naming
Boston Naming Test: total score −9.9 [−13.6; −6.1] <0.001*** 2.22 [−1.5; 5.9] 0.2 −0.1 [−0.6; 0.3] 0.59
a Estimated mean difference between persons with DS with IQ < 40 and persons with DS with IQ ≥ 40 adjusted for gender and age.
b Confidence Interval.
c Estimated mean differences between female and male persons with DS adjusted for IQ and age.
d Estimated mean differences associated to one year of age difference in persons with DS adjusted for IQ and gender.
e Milliseconds.
* Significant estimated effects of the variable of interest (p<0.05).
** Significant estimated effects of the variable of interest (p<0.01).
*** Significant estimated effects of the variable of interest (p<0.001).
+ Marginal non-significant estimated effects of the variable of interest.
Magnitude of Cognitive Deficits in DS Adults
The results of this study support the demonstration (Abbeduto
et al., 2001; Laws and Bishop, 2004; Næss et al., 2011) that
language impairment is the strongest cognitive disturbance in
young DS adults with receptive abilities being more preserved
than expressive skills. In addition, and as previously reported,
the relative strength of visuospatial processing over verbal tasks
suggests that language impairment is the primary landmark of
global intellectual impairment in DS (Lanfranchi et al., 2004;
Edgin et al., 2010b). After language, attention and executive
functions differed more from standard norms, with verbal span
capacity and verbal fluency presenting the strongest deficiencies,
followed by workingmemory; in contrast, planning was relatively
more preserved. These results concur with the portrayal of a
broad, marked dysexecutive syndrome in DS (Rowe et al., 2006;
Lanfranchi et al., 2010) probably due to the reduced size of the
prefrontal cortex (Contestabile et al., 2010; Lott and Dierssen,
2010), in particular of the anterior cingulate gyrus, medial,
and dorsolateral prefrontal cortices as reported in neuroimaging
studies of DS adults (Raz et al., 1995; White et al., 2003;
Carducci et al., 2013). Areas such as these actively contribute to
mnemonic processing and executive control in euploid subjects
(Braver, 2001; Wager and Smith, 2003; Blumenfeld et al., 2011),
thus generalized impairment of high order frontal-dependent
processes, together with language, represent a crucial target for
therapeutic intervention in DS.
Overall performance in episodic memory was also poor
although superior to language, attention, and executive functions.
It is noteworthy that our results showed a better preservation
of hippocampal-dependent memory processes, such as storage
and consolidation, compared to frontal-mediated processes
(information coding, retrieval strategies and attention control) in
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TABLE 4 | Impact of intellectual quotient (IQ), gender, and age on executive functioning in Down syndrome participants.
Down syndrome
Intelligence Quotient (<40 vs. ≥ 40) Gender (female vs. male) Age
Estimatea 95% CIb p-values Estimatec 95% CI p-values Estimated 95% CI p-values
EXECUTIVE FUNCTIONS
Verbal fluency
Semantic word fluency −2.6 [−4.4; −0.8] 0.006** −0.1 [−1.9; 1.7] 0.87 0.1 [−0.1; 0.3] 0.29
Working memory
SSP visual span backwards −0.8 [−1.4; −0.1] 0.02* 0.7 [0.05; 1.4] 0.03* 0.03 [−0.04; 0.1] 0.42
Digit span backwards −0.3 [0.86; 0.15] 0.16 0.43 [−0.1; 0.9] 0.09 −0.01 [0.04; 0.6] 0.64
Planning
ToLDx: total correct score −1.0 [−1.6; −0.5] <0.001*** 0.9 [0.4; 1.5] 0.002** −0.03 [−0.1; 0.03] 0.36
ToLDx: total move score 26.3 [10.0; 42.7] 0.002** −20.9 [−37.2; −4.6] 0.01* 0.9 [−1.0; 2.8] 0.33
ToLDx: problem-solving time (se) 180.3 [58.2; 302.4] 0.004** −143.9 [−265.6; −22.1] 0.02* 9.2 [−5. 1; 23.5] 0.20
Mental flexibility
Weigl sort test: total score −0.3 [−1.0; 0.3] 0.32 1.2 [0.5; 1.9] 0.001** −0.02 [−0.1; 0.1] 0.62
Inhibition
Cats and dogs: total time (s) 7.6 [0.6; 14.7] 0.03* −2.4 [−9. 5; 4.6] 0.48 0.2 [−0.7; 1.0] 0.66
Cats and dogs: correct score −0.6 [−1.1; −0.1] 0.02* −0.01 [−0.5; 0.5] 0.96 −0.02 [0.1; 0.03] 0.44
a Estimated mean difference between persons with DS with IQ < 40 and persons with DS with IQ ≥ 40 adjusted for gender and age.
b Confidence Interval.
c Estimated mean differences between female and male persons with DS adjusted for IQ and age.
d Estimated mean differences associated to one year of age difference in persons with DS adjusted for IQ and gender.
e Seconds.
* Significant estimated effects of the variable of interest (p < 0.05).
** Significant estimated effects of the variable of interest (p < 0.01).
*** Significant estimated effects of the variable of interest (p < 0.001).
DS. Findings substantiated by the higher performance exhibited
in the recognition and cued recall trials as compared to free
recall, and by the higher ratio of perseverative errors compared
to intrusions in the verbal learning task (see Supplementary
Results). This mnemonic profile indicates that poor monitoring
and executive control, rather than storage difficulties, are mainly
responsible for poor memory performance. In this regard,
structural neuroimaging studies have related impaired memory
performance in DS adults with reductions in the prefrontal,
hippocampus, and parahippocampal areas of these subjects
(Krasuski et al., 2002; Teipel et al., 2004; Beacher et al., 2005).
Postmortem histological studies have, moreover, consistently
demonstrated that the dendritic morphology of hippocampal
neurons is compromised in DS adult brains (Ferrer and Gullotta,
1990; Takashima et al., 1994). In summary, our results indicate
executive dysfunction as a major factor underlying memory
impairment in DS. Thus, effective therapies targeting prefrontal-
dependent executive functions in this population would enhance
cognitive performance.
Effects of IQ, Gender, and Age on Cognitive and
Functional Outcomes in DS
We explored the association of clinical and sociodemographic
variables such as IQ, gender, and age with cognitive and
functional performance in DS. Our regression analyses, in
concurrence with other authors, revealed that the explanation for
the extensive variability found in the neurocognitive performance
of DS adults lies in the primary variable of the IQ level.
The most consistent associations with IQ were found with
language, its use in everyday functioning (learning of literacy
basics, communication skills, social abilities, and efficient use
of community resources), and with global adaptive competence.
No effect of IQ was observed, however, on quality of life
outcomes. A finding that could partly be explained by the fact
that in euploids, emotional aspects are more closely related to
QoL perception than IQ (Takeuchi et al., 2014). The use of
parent-proxy measures for determining QoL perception in DS is,
nevertheless, a surrogate and a probably biased outcome based on
QoL self-perception in these subjects.
It is noteworthy that gender showed a widespread influence
on cognitive variables whilst its impact on functional outcomes
was minor. From our analyses we can conclude that men with
DS perform at a significantly poorer level than DS women,
in particular with respect to episodic memory and executive
processing. They also exhibit poorer functional academic skills
in everyday life, but present a higher QoL perception concerning
their physical well-being. Although the differences observed
in cognitive performance between genders are mild, they may
explain the higher IQ level and better competence exhibited
by women in everyday functioning, in particular related to
command of language. Other studies have also reported that
women with trisomy 21 display a higher level of cognitive
and adaptive functioning than DS men (Lund, 1988; Määttä
et al., 2006). Taken together, these findings suggest that gender
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TABLE 5 | Impact of intellectual quotient (IQ), gender, and age on functional outcomes in Down syndrome participants.
Down syndrome
Intelligence Quotient (<40 vs. ≥ 40) Gender (female vs. male) Age
Estimatea 95% CIb p-values Estimatec 95% CI p-values Estimated 95% CI p-values
ADAPTIVE BEHAVIOR
ABAS-Communication −8.7 [−13.9; −3.6] 0.001** 4.2 [−1.0; 9.4] 0.11 0.1 [−0.7; 0.8] 0.82
ABAS-community use −9.7 [−15.0; −4.4] <0.001*** 2.8 [−2.5; 8.1] 0.29 0.5 [−1.1; 1.1] 0.13
ABAS-functional academics −13.3 [−20.4; −6.3] <0.001*** 9.0 [1.9; 16.1] 0.01* 0.1 [−0.1; 1.0] 0.77
ABAS-home living −5.6 [−10.6; −0.6] 0.02* 4.2 [−0.8; 9.3] 0.09 0.4 [−0.2; 1.0] 0.17
ABAS-health and safety −5.8 [−9.7; −1.8] 0.005** 0.5 [−3.5; 4.5] 0.81 0.2 [−0.3; 0.7] 0.42
ABAS-leisure −2.5 [−7.6; 2.5] 0.32 1.2 [−3.8; 6.3] 0.62 −0.2 [−0.8; 0.4] 0.50
ABAS-self-care −1.5 [−5.1; 2.2] 0.42 2.4 [−1.3; 6.0] 0.20 0.03 [−0.4; 0.5] 0.85
ABAS-self-direction −8.7 [−14.8; −2.5] 0.006** 4.9 [−1.2; 11.0] 0.11 0.2 [−0.6; 0.9] 0.64
ABAS-social skills −7.6 [−12.4; −2.8] 0.002** 1.8 [−2.9; 6.6] 0.44 −0.5 [−1.0; 0.1] 0.09
ABAS-work – – – – – –
ABAS-total score −63.4 [−100.4; −26.4] 0.001** 31.1 [−6.1; 68.3] 0.10 0.8 [−3.6; 5.2] 0.71
QUALITY OF LIFE
Kidscreen 27-physical 0.6 [−1.1; −2.2] 0.49 −1.7 [−3.3; −0.05] 0.04* −0.2 [−0.4; 0.03] 0.09
Kidscreen 27-psychological 0.5 [−1.2; −2.3] 0.53 0.2 [−1.5; 1.9] 0.82 −0.2 [−0.4; −0.01] 0.03*
Kidscreen 27-autonomy and parents 0.1 [−1.1; 1.4] 0.80 1 [−0.3; 2.3] 0.11 −0.05 [−0.2; 0.1] 0.46
Kidscreen 27-peers and social 0.5 [−1.4; 2.4] 0.60 0.9 [−1.0; 2.8] 0.35 −0.05 [−0.3; 0.2] 0.66
Kidscreen 27-school – – – – – –
Kidscreen 27-total score 2.8 [−3.9; 9.6] 0.39 −1.0 [−7.6; 5.6] 0.75 −0.9 [−1.7; 0.1] 0.03*
a Estimated mean difference between persons with DS with IQ < 40 and persons with DS with IQ ≥ 40 adjusted for gender and age.
b Confidence Interval.
c Estimated mean differences between female and male persons with DS adjusted for IQ and age.
d Estimated mean differences associated to one year of age difference in persons with DS adjusted for IQ and gender.
* Significant estimated effects of the variable of interest (p < 0.05).
** Significant estimated effects of the variable of interest (p < 0.01).
*** Significant estimated effects of the variable of interest (p < 0.001).
may exert a relevant modulating effect on cognitive functioning
in DS participants favoring women, which is not the case in
healthy participants. The poorer QoL status in young women
with DS compared to men, especially with respect to their
physical well-being, may not be characteristic of DS associated
with gender, since it has also been reported in woman from
euploid population (Torsheim et al., 2006; Michel et al.,
2009).
The impact of age on neurocognitive outcomes was negligible
and restricted to QoL perception. In a similar manner to healthy
adolescents and young adults, increasing age in DS participants
was associated with a decline in QoL, in spite of the fact that
women reported poorer outcomes compared to men (Bisegger
et al., 2005; Michel et al., 2009). Thus, lower QoL with increasing
age is not a distinctive trend in DS. No significant impact of
age was found on cognitive and adaptive behavior outcomes,
probably due to the age range of our sample (16–34 years
old), representative of late adolescence and adulthood when the
negative consequences of premature aging upon cognition and
everyday life competence have not yet been detected. Our results
suggest that during this period overall cognitive capacity in DS
adults has probably reached a plateau, similar to the scenario
of normally developed adults who reach their peak performance
between 18 and 30 years of age (Peña-Casanova et al., 2012).
Taken together, our results emphasize the need to explore the
modulating effects of IQ, gender, and age on cognitive enhancing
treatments in the DS population.
Relationship to Functional Outcome in DS
Participants for Interventional Studies
We explored the associations between cognitive performance, IQ,
and functional outcomes of adaptive behavior and QoL in DS.
The aim was to identify specific relationships between cognitive
performance and different aspects of functional outcome that
could potentially serve for expecting functional change following
interventional studies. Cognitive-related outcomes were closely
linked to functional aspects of language and global adaptive
competence in everyday life. It is worth mentioning that auditory
comprehension and functional academic measures have a great
potential as end-point measures of therapeutic intervention for
clinical trials: the former as a cognitive key target for therapeutic
intervention, and the latter as a primary functional outcome
measure of clinical efficacy.
According to the results obtained in the regression analysis, it
could be argued that IQ could be a good predictor of functional
outcome for longitudinal interventional studies. Specific
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FIGURE 2 | Radar plot representing the statistically significant
differences in cognitive performance between men and
women with Down Syndrome (DS) on attention, memory,
language and executive functioning components. Axis values
indicate the performance in percentage relative to the women’s
performance, which has been set to 100%. Men with DS
performed significantly poorer than women in all four cognitive
domains.
cognitive capacities, however, showed consistent associations
with functional outcomes in the univariate analysis. IQ remains
stable during adult life whilst cognitive capacities underlying
intellectual status, such as attention, memory, language, and
executive functions, are dynamic throughout the lifespan. These
changes in cognitive capacity provide greater sensitivity for
assessing the efficacy of therapeutic interventions. In addition,
these cognitive capacities can be precisely measured with specific
tests that are sensitive to clinical and subclinical changes. The
fact that these cognitive measures are considered a proxy of
such subclinical changes, closely related with the abnormal
functioning of prefrontal-temporal brain networks, is extremely
important when testing new therapeutic strategies for mental
disability. Currently, a major caveat of clinical trials targeting
functional change in DS is that follow-up periods tend to be too
short (less than 12 months on average), while improvements in
complex functional skills in DS require longer periods (Costa,
2011; Boada et al., 2012) We agree with this view but suggest that
subclinical cognitive gains related to positive pharmacological
and/or behavioral interventions in DS may be sufficient for a
mild, but significant, impact on everyday life functioning, similar
to what we can expect in other pathological conditions such as
AD (Insel et al., 2013). Studies with extended follow-up periods
under active treatment are needed to probe our hypotheses
and ensure the validity of the proposed linkages as clinically
meaningful for estimating functional change in interventional
studies.
Limitations
Several limitations should be considered when interpreting the
results of our study. First, the neurocognitive assessment tools we
employed may have influenced the DS cognitive profile observed.
The majority of the tests included in our TESDAD battery
are, nevertheless, recognized as valid and feasible for tracking
cognitive deficits in pathological conditions (Ersche et al., 2012;
Juncos-Rabadán et al., 2014), they are well standardized and
extensively normalized, and acceptable for DS participants with
mild to moderate mental disability (Devenny et al., 2002; Ball
et al., 2008; De la Torre et al., 2014). Floor effects were observed
for the verbal and visual backward span and mental flexibility
tasks, whereas ceiling effects where shown in a few episodic
memory variables and in the response inhibition test regarding
task accuracy but not for time of response. These limitations were
found mainly in specific tests developed for mentally disabled
individuals (Weigl, Cats and Dogs and CRT). Although, these
findings suggest that these tasks could be replaced, we can
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still consider them suitable for the assessment of the selected
population due that these were not found for all variables
in each of the mentioned tests (e.g., free recall measures in
the CRT), or provide an affordable evaluation of high-order
executive capacities in intellectual disability (e.g., Weigl). One
of the few commonly used cognitive batteries is the Arizona
Battery (ACTB), developed for school age children and young
adults with DS (age range 7–30 years), employing the mental-
age matched procedure (Edgin et al., 2010a). The principal
differences between the ACTB and the TESDAD battery are that
TESDAD allows a more thorough, direct cognitive assessment of
the main mnemonic and executive components with language
being a key domain, whereas ACTB includes a deeper assessment
of executive-behavioral dysfunction using questionnaires for
parents. In addition, the TESDAD was also designed to
be sensitive to mild cognitive impairment, making this tool
potentially valid for capturing deterioration in the prodromal
stage. Another limitation is that the TESDAD only explores
“cool-cognitive functions,” whereas “hot-cognitive processing”
involving emotional, motivational, and rewarding aspects are
omitted. We focused our assessment on cool-conscious high
reasoning processes, in particular on executive and mnemonic
processing supported by the hippocampus and frontal cortices,
because preclinical and clinical evidence consider those to be
critical targets for therapeutic intervention in DS. Nonetheless,
the TESDAD Battery should undergo further modifications to
integrate new feedback provided by future preclinical and clinical
evidence. Another drawback is that IQ estimation within the
lowest range (IQ < 40) could not be exactly determined with the
K-BIT. In addition, the fact that the Kidscreen-27 questionnaire
was designed for assessing younger individuals (8–18 years of
age), may have partly compromised its sensitivity for determining
QoL perception in young adults. The lack of an overall composite
score integrating cognitive and functional outcomes is another
important limitation, ongoing issue for the TESDAD battery.
This comprehensive score would be a valuable asset for globally
evaluating treatment effects in longitudinal studies. Finally, the
lack of a test-retest reliability assessment of the overall battery is
another important drawback. Nonetheless, the selection of tests
was based upon previous reliability studies carried for each of
these tools (Strauss et al., 2006).
Conclusion
In summary, the TESDAD battery is a useful tool for a
standardized neurocognitive assessment of DS in clinical trials.
The most relevant features of this battery include a chronological
age-matched approach, high sensitivity for detecting mild to
moderate cognitive deficits, and a strong relationship to clinically
relevant functional measures. These features make the battery
suitable for capturing changes derived from therapy which allow
its efficacy to be established.
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